TheraRadar
← Back
Data updated: Mar 29, 2026

ARRAY BIOPHARMA INC

OncologyGastroenterology
Pharma

ARRAY BIOPHARMA INC is a pharmaceutical company focused on Oncology, Gastroenterology. Key products include MEKTOVI.

2018
Since
2
Drugs
-
Trials
7
Approved (2yr)

Key Drugs

MEKTOVI
binimetinib
Oncology
MEK1 2 indications · 2018

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

BRAFTOVI 2026-02-24
Efficacy
BRAFTOVI 2026-02-24
Efficacy
BRAFTOVI 2025-03-12
Efficacy
MEKTOVI 2025-03-12
Efficacy
BRAFTOVI 2024-12-20
Efficacy
BRAFTOVI 2024-09-12
Efficacy
MEKTOVI 2024-09-12
Efficacy
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 86%
1 drugs
Gastroenterology 14%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology
Takeda big-pharma
Oncology, Gastroenterology
Gilead Sciences biotech
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology